Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. - Wikidata - wikimedia - TriplyDB

Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.

Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.

http://www.wikidata.org/entity/Q33944180

about

Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.Cardiac iron across different transfusion-dependent diseases.Longitudinal analysis of heart and liver iron in thalassemia major.Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

P2860

Q33909024-D9E885BE-61CE-41B9-A702-C69D976A9A9B Q33958560-63CC474F-6D44-4726-84C0-1B3C2412CB02 Q36915941-60221973-19D1-4DC0-8C5E-8D2197E45BDA Q37809009-39BC7285-258F-4956-B5FA-8B44799B6B65 Q38219588-83748A74-21DB-4540-877C-6976BC1B5235 Q40896307-A9546B2B-B2A8-44B1-BECC-02D12084A658 Q52575650-4A5841E0-4C6F-418D-B4D4-EB9C85EA598C Q57998367-968E5029-7998-4300-ACCF-268A403C66CA

P2860

Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.

http://www.wikidata.org/entity/Q33944180

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Comparison of twice-daily vs o ...... model of iron cardiomyopathy.

@ast

Comparison of twice-daily vs o ...... model of iron cardiomyopathy.

@en

type

label

Comparison of twice-daily vs o ...... model of iron cardiomyopathy.

@ast

Comparison of twice-daily vs o ...... model of iron cardiomyopathy.

@en

prefLabel

Comparison of twice-daily vs o ...... model of iron cardiomyopathy.

@ast

Comparison of twice-daily vs o ...... model of iron cardiomyopathy.

@en

P1433

Q33944180-B3A6B827-6AA5-4A4A-B059-0262B9DF3242

P1476

Q33944180-DC753750-23F2-4FE5-B1DE-39EE45E2C214

P2093

Q33944180-2EECF769-BD24-440B-8BF9-89AEE963133D

Q33944180-3087E3DD-7F82-4ED4-AF3C-56D2A0FC2A58

Q33944180-8547C4E9-3632-4771-91C2-17BC77EA7916

Q33944180-921F63F5-8354-488F-A542-BBD2247555B5

Q33944180-A58CD50B-84F9-46A1-8F24-7E2448DF03B1

P2860

Q33944180-3D1A31F5-778E-40B1-B27E-39AD3F87839D

Q33944180-494A5DEB-F6C0-4D34-8C30-180B1FF98077

Q33944180-60C2AFFE-13BF-4614-AFD5-2C76192DA9FB

Q33944180-86450365-0DA1-44A6-A544-6F483996AB1F

Q33944180-8CA270C1-911E-4921-9141-EAD4C726F6CB

Q33944180-8FD257FD-A88E-45C0-95E8-2BC1DE546E6B

Q33944180-A228D883-B87F-4C7B-A317-3A0351CE1F7E

P304

Q33944180-C910BD66-FD9B-4E8F-A9FF-69B884FFE72C

P31

Q33944180-B9F71AD9-5CBA-4D93-9E67-B762C7F4B692

P356

Q33944180-E20DAF0F-D0F2-46EF-B7B7-B8804271D8B3

P433

Q33944180-45593EC7-2A5E-4704-AE5C-40C0CA494BB2

P478

Q33944180-7D1083F2-FF73-47FB-9131-B2288222084F

P577

Q33944180-90413C5F-1206-48B9-AA2F-AC2A8D00E586

P5875

Q33944180-C7864CEF-15B4-43CC-9B4D-9D99E860DC61

P698

Q33944180-502EE778-28CE-44B2-BC5A-54AFBB756C7D

P932

Q33944180-7069676D-6AA2-4688-95A1-D47571352BC0

P356

J.EXPHEM.2007.04.001

P1433

Experimental Hematology

P1476

Comparison of twice-daily vs o ...... model of iron cardiomyopathy.

@en

P2093

Hanspeter Nick

http://www.w3.org/2001/XMLSchema#string

John C Wood

http://www.w3.org/2001/XMLSchema#string

Maya Otto-Duessel

http://www.w3.org/2001/XMLSchema#string

Michelle Aguilar

http://www.w3.org/2001/XMLSchema#string

Rex Moats

http://www.w3.org/2001/XMLSchema#string

P2860

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.

High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.

In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human.

Survival and disease complications in thalassemia major.

P304

1069-1073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EXPHEM.2007.04.001

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6249877

http://www.w3.org/2001/XMLSchema#string

P698

17588475

http://www.w3.org/2001/XMLSchema#string

P932

2892931

http://www.w3.org/2001/XMLSchema#string